Navigation Links
AMDL Expands Drug Distribution in China With Additional Agreement, Valued at $2.3 Million Annually
Date:10/11/2007

TUSTIN, Calif., Oct. 11 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), headquartered in Tustin, California, with operations in Shenzhen, Jiangxi and Jilin, China, through its wholly owned subsidiary Jade Pharmaceutical Inc. (JPI), is an international biopharma company that engages in the development, manufacture and marketing of proprietary pharmaceutical and diagnostic products. AMDL announced today that JPI has signed an agreement with Heze Mudan Medicals Co. Ltd. to distribute Domperidone tablets in the Province of Shandong and the surrounding areas, one of the most affluent regions in China.

Domperidone is an important medicine for treating nausea and vomiting. JPI's generic version of this product is significantly lower priced than competitors. The contract is subject to minimum sales which will be reviewed annually and is expected to add at least $2.3 million in annual revenues.

Frank Zheng, managing director of JPI, said this transaction puts the Company on the path to building sales in China by as much as $24 million over the next 12 months. Gary Dreher, CEO of AMDL, said this and other recently signed contracts will assist in the effort to meet the goal of building annual sales to $100 million over the next four to five years.

About JPI: Jade Pharmaceutical has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiary, Jade currently manufactures large volume injectable fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.

About AMDL: More information about AMDL and its products can be obtained at http://www.amdl.com .

Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Contact: AMDL, Inc.

Paul Knopick

AMDL Investor Relations

Direct Line: 949.707.5365

Voice Mail: 714.505.4460


'/>"/>
SOURCE AMDL, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. WARF expands license agreement with Advanced Cell Technology
2. Verizon expands broadband service in Wisconsin
3. Bandwidth provider expands in Milwaukee
4. Wisconsins biodiesel network expands
5. Quad/Graphics expands reach in western states
6. University of South Florida expands GE Healthcare relationship
7. Metavante expands healthcare payments division
8. Fiserv expands services to health plan market
9. Bone Care expands patent protection of core drug offering
10. SBC and AT&T merger expands global reach for Wisconsin businesses
11. Expetec expands IT staff services in Wisconsin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... 2016 , ... Supplyframe, the Industry Network for electronics hardware ... . Located in Pasadena, Calif., the Design Lab’s mission is to bring together ... built and brought to market. , The Design Lab is Supplyframe’s physical representation ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the ... the Dow Jones Industrial Average edged 0.27% lower to finish ... 0.17%. Stock-Callers.com has initiated coverage on the following equities: Infinity ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... ). Learn more about these stocks by accessing their free ...
Breaking Biology Technology:
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
Breaking Biology News(10 mins):